-
-
-
-
-
-
-
KALA BIO receives $6M investment, appoints new CEO
-
-
-
-
-
-
-
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
-
-
-
-
-
-
-
UPDATE: Wedbush Assumes Kala Pharmaceuticals (KALA) at Outperform
-
-
-
-
-
-
-
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Dise
-
1,188,218 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

